BACKGROUND: Clinical characteristics of the international population with severe asthma are unknown. Intercountry comparisons are hindered by variable data collection within regional and national severe asthma registries. We aimed to describe demographic and clinical characteristics of patients treated in severe asthma services in the United States, Europe, and the Asia-Pacific region.
Severe asthma is defined as "asthma which requires treatment with high dose inhaled corticosteroids (ICS) plus a second controller (and/or systemic corticosteroids) to prevent it from becoming 'uncontrolled,' or which remains 'uncontrolled' despite this therapy." 1 Other definitions include lack of control with use of maximal optimized therapy and treatment of contributory factors. 2 Severe asthma is thought to affect approximately 5% to 10% of the total population with asthma, 1 although a large prevalence range (1.8%-38%) has been reported. 3 Severe asthma is associated with significant morbidity 4 and mortality [5] [6] [7] and treatment, 8 psychological, 9 and socioeconomic 10 burdens, with much of the cost attributable to oral corticosteroid (OCS)-induced morbidity. 11, 12 The cost per patient of severe asthma can be tenfold higher than that of mild disease, accounting for more than 60% of asthma-related health-care costs. 13 Many patients are unable to maintain full-time employment, 14 with a high degree of presenteeism and absenteeism reported. 15 The World Health Organization emphasizes asthma's contribution to the global symptom and economic burden and calls for "better surveillance to map the magnitude of chronic respiratory diseases and analyze their determinants.and to monitor future trends." 16 The Global
Asthma Report stresses the need for asthma monitoring to be ongoing, appealing for countries to conduct asthma surveillance, with regular investigation of trends. 17 Regional and national severe asthma registries already exist and collect valuable country-specific data. [18] [19] [20] [21] [22] [23] [24] [25] However, they typically contain relatively small numbers and tend to target specific subsets of severe asthma. Combining data is delayed until individual registry data are published and is hindered by different definitions used and variables collected. The International Severe Asthma Registry (ISAR; http:// isaregistries.org/), the first worldwide adult severe asthma registry, overcomes some of these limitations 26, 27 and answers the World Health
Organization and Global Asthma Report calls to action. 16, 17 In partnership with national and regional registries, ISAR collects patient-level, pseudonymous, longitudinal, real-life, standardized, high-quality data, using a set of core variables, from countries across the world for ethically approved research purposes. 27 ISAR contains data in a greater breadth of patients within the severe asthma definition and has sufficient power to answer important clinical questions. The aim of this article is to describe the demographic and clinical characteristics of patients with severe asthma treated in secondary and tertiary asthma centers in the United States, Europe, and the Asia-Pacific region and to study intercountry differences.
Materials and Methods

Patients
Because this is a historical, registry study, patients were not recruited but rather included into ISAR from other existing and newly created registries. ISAR essentially acts as a data custodian. Participating countries retain ownership of their own data but have agreed to provide access to, and share anonymous patient-level data with, ISAR for approved research purposes. Patient data are transferred to the ISAR database at regular intervals. Details of how data are extracted from national registries to ISAR are provided in the online Department of Medicine, University of Colorado Hospital, Aurora,supplement (e-Appendix 1). A country lead has been identified for each registry and is responsible for overseeing data collection, including combining data from any satellite sites, before making the countrywide data available to ISAR. This approach, in effect, allows for the creation of a locally hosted central registry for the country's combined data, which can be used to enhance local-and international-level research. Full details about asthma diagnostic criteria and the definition of severe asthma for each of these registries are provided in the online supplement (e- Tables 1, 2) . Patients in ISAR are 18 years or older, received treatment at Global Initiative for Asthma (GINA)
Step 5 or had uncontrolled asthma at GINA Step 4 (at inclusion), 1, 28 and provided consent for their data to be included (except in the United States, where consent was not required because data were deidentified). Smokers and those with asthma-COPD overlap (ACO) were not excluded. ISAR is currently developing a protocol to identify patients with ACO within its severe asthma cohort. These eligibility criteria were chosen to reflect patients with severe asthma in the real-world setting and to broaden the scope to include patients with uncontrolled moderate to severe asthma.
Data Collected
Aggregated baseline demographic and clinical data for prespecified analyses were transferred to ISAR from secondary and tertiary severe asthma centers in the United Kingdom, Italy, South Korea, and Australia. Patient-level data were contributed by the United States. Patients in the US registry were identified by meeting the ISAR eligibility criteria on the basis of their diagnostic labeling medications to assess GINA Step 4 or Step 5 treatment and asthma control test score and/or prebronchodilator FEV 1 < 80% predicted to ascertain asthma control status from their retrospective electronic medical health records. Data were collected from the following registries from December 2014 to December 30, 2017 27 Those presented in this article are summarized in e- Tables 3 and 4 . The number of exacerbations was defined as the number requiring rescue systemic corticosteroids in the past 12 months. The United States used duration of OCS as a proxy for exacerbation (assuming one OCS course lasts $ 7 days), in line with GINA 2018 recommendations and previously published research and based on discussion with the site investigator. 28, 29 A retrospective analysis of National Jewish Health prescriptions showed that most prednisolone prescriptions were for at least 7 days for short-term use. The number of hospitalization and ED admissions for asthma was the number in the past 12 months. The number of times invasive ventilation was used was the number of episodes before data extraction. Comorbidity was based on a formal diagnosis or reliably inferred from relevant prescription data. For the United States, comorbidity data were captured using International Classification of Diseases, Tenth Revision codes for active diagnosis of comorbidity. Prescription data were used as a supplement to identify the comorbidity status of allergic rhinitis (AR) and eczema because their active diagnosis was underreported in the electronic medical records data. This finding was confirmed by the site lead (E. W.) and additional practitioners at the clinic. In addition to tracking regular OCS use (defined as $ 90 days of OCS use in a year), to capture risk for systemic corticosteroid adverse effects, intermittent OCS use was defined as the prescription for repeated OCS use and/or $ 2 exacerbations in a 1-year period. 30 Asthma control was categorized as controlled, partly controlled, or uncontrolled according to GINA criteria, 28 determined using the Asthma Control Test questionnaire 31 or the Asthma Control Questionnaire.
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Ethics and Governance
This study was designed, implemented, and reported in accordance with the European Network Centres for Pharmacoepidemiology and Pharmacovigilance (European Medicines Agency 2014; EUPAS25489; http://www.encepp.eu/encepp/viewResource.htm?id=27888) and performed in compliance with all applicable local and international laws and regulations. Governance was provided by the Anonymised Data Ethics Protocols and Transparency committee (protocol 2249). All registries participating in ISAR received ethical approval in their own countries and obtained regulatory agreement to provide deidentified data to ISAR in compliance with country-specific international data transfer laws and legislation and their relevant ethical boards and organizations. All patient-level data extracted and transferred from the United States were deidentified and entered into the research database as anonymized patient identification numbers.
Statistical Analysis
Data were assessed using Stata version 14 (StataCorp) or SAS version 9.4 or 9.5 (SAS Institute) according to a predefined data analysis plan to minimize bias. Descriptive statistics were reported as categorical variables for all variables for the overall and country-specific patient populations. Health-care resource use (HCRU), IgE count, blood eosinophil count (BEC), and comorbidities also were stratified by severe asthma status and sex for the overall population.
Results
Demographic Characteristics
The study included 4,990 eligible patients with individuallevel data from the United States (n ¼ 3,286) and aggregate data from the United Kingdom (n ¼ 696), South Korea (n ¼ 439), Italy (n ¼ 310), and the SAWD registry (n ¼ 259). Mean (SD) age was 55 (15.9) years, and mean (SD) age at asthma onset was 30.7 (17.7) years. Patients were predominantly female (59.3%), were aged 55 to 79 years (52.1%), were white (72.6%), had never smoked (60.5%), and were overweight or obese (70.4%); 34.9% were at GINA Step 5; and 57.2% had poorly controlled disease. A total of 51.1% of patients were receiving regular intermittent OCS, and 25.4% were receiving biologics (72.6% for those at GINA Step 5). Mean (SD) exacerbation rate was 1.7 (2.7) per year (Table 1) . South Korea had the oldest patients, the lowest prevalence of patients who were overweight or obese, and the highest prevalence of current smokers (12.1%). Approximately one-third of individuals from the SAWD registry (30.0%), South Korea (33.9%), and the United States (36.8%) were exsmokers (e- Table 5 ).
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Clinical Characteristics
Severity and Lung Function: Most patients had uncontrolled asthma at GINA Step 4 (Fig 1) . There was a higher proportion of women both among patients with uncontrolled asthma at GINA Step 4 (59.3%) and among patients with asthma at GINA Step 5 (59.4%). Patients from the United Kingdom and Italy tended to have more severe disease, and those from the United States and South Korea tended to have the least severe compared with patients in other countries (Fig 1) .
Percent predicted FEV 1 and FVC values appeared to be independent of severity, showed some intercountry variability, and showed little postbronchodilator improvement ( Table 2 ). The mean (SD) postbronchodilator FEV 1 /FVC was 0.69 ( 0.13) for patients at GINA Step 5 and 0.71 (0.13) for those with uncontrolled asthma at GINA Step 4 ( Table 2) , indicating a substantial presence of fixed airway obstruction. The percentages of patients with FEV 1 / FVC < 0.7 were 43% and 47% for GINA Step 4 and Step 5, respectively. Bronchoconstriction was considered irreversible 33 for those in both severity groups and irrespective of smoking history. Some intercountry variability was noted (Table 3) . 33 The number refers to the total number of patients with nonmissing data. Percentages may not total 100% because of rounding. ISAR ¼ Internal Severe Asthma Registry. 
Patients (%)
FEV 1 and FVC data are presented as mean (SD) % predicted. The % predicted data are based on aggregate-level data from the United Kingdom, United States, South Korea, and Italy; aggregate data for % predicted lung function were not available for patients in the SAWD registry. FEV 1 /FVC is derived from patient-level lung function data from the United States, South Korea, and Italy. GINA ¼ Global Initiative for Asthma. See Table 1 legend for expansion of other abbreviation. a The number refers to the total number of patients with nonmissing data. b Patient-level data were used to compute the FEV 1 /FVC ratio; these data were not available for the United Kingdom but were available for 12 and eight patients (GINA Steps 4 and 5, respectively) from South Korea.
c Data were not available for postbronchodilator % predicted FVC for Italy. Tables 1 and 2 legends for expansion of other abbreviations. a The number represents the total number of patients with nonmissing data and includes patients at both GINA Step 4 and GINA Step 5. Patient-level data from the United States and Italy were used to compute bronchodilator reversibility (% change in lung function); these data were not available for the United Kingdom but were available for 20 patients from South Korea.
chestjournal.org Exacerbations are defined as requiring rescue steroids in the past year or are defined according to OCS duration (assuming one course lasts $ 7 days). Regular OCS is defined as a prescription for $ 90 days of OCS exposure in the observation year. Intermittent OCS use is defined as a prescription for repeated OCS use and/or $ 2 exacerbations (treated with OCS). OCS ¼ oral corticosteroid; SAWD ¼ Severe Asthma Web-based Database. See Tables 1 and 2 The duration of OCS exposure was used as a proxy for asthma exacerbation assuming one course lasts $ 7 days. of severe asthma means that for the first time this population can be properly studied and characterized.
Age at Onset: The mean (SD) age at onset was 30.7 (17.7) years; 77.5% of patients developed asthma after the age of 12 years and 34.4% developed it after the age of 40 years. Patients from the United Kingdom and the SAWD registry developed asthma slightly earlier than this, and those from South Korea and Italy slightly later (Table 4 , e- Table 6 ).
Asthma Control, Exacerbations, and HCRU: Figure 2 shows the proportion of patients with well-controlled, poorly controlled, and uncontrolled asthma 31, 32 in the total population and also in each of the individual registries. At entry to their national registry, 57.2% of patients had poorly controlled asthma; this percentage was highest in the United Kingdom and the SAWD registry and lowest in Italy and South Korea. The proportions of patients with well-controlled, partly controlled, and uncontrolled asthma were similar in the GINA Step 4 (uncontrolled asthma at entry) and GINA
Step 5 groups (e -Fig 1) . The mean (SD) number of exacerbations (past 12 months) was 1.7 (2.7). Onequarter of patients reported $ 4 exacerbations (Fig 3) . The number of exacerbations was driven by severity, with most patients with uncontrolled asthma at GINA
Step 4 (at inclusion) reporting 0 exacerbations (71.1%), whereas 42.5% of patients at GINA Step 5 reported $ 4 exacerbations. The mean number of exacerbations was lowest in the United States and South Korea and highest in the United Kingdom (Fig 3, Table 4 ). HCRU was high overall but highest in the United Kingdom and lowest in South Korea (Fig 4) , and was slightly higher for patients at GINA
Step 5 (e -Fig 2, e- Table 6 ).
IgE Concentration: One-half of the patient population with severe asthma had low IgE concentrations (< 150 IU/mL) (Fig 5A) . (Fig 5C) .
Comorbidities: AR was the predominant comorbidity (49.4%) in the total population, followed by chronic rhinosinusitis (CRS; 21.4%), eczema (9.6%), and nasal polyps (NPs; 7.3%). AR was the predominant comorbidity in all countries. The United States had the highest prevalence of comorbid CRS (26.8%), the SAWD registry had the highest eczema prevalence (20.5%), and Italy had the highest NP prevalence (22.3%) (e- Fig 3, e- Table 6 ). 
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Treatment: Across all patients (ie, those at GINA Step 4 or Step 5), 51.1% were receiving repeated intermittent OCS. Those from the United Kingdom, Italy, and the SAWD registry had the highest intermittent OCS use, and the United States had the lowest (Table 4 ).
All patients with uncontrolled asthma at GINA Step 4 were receiving inhaled corticosteroid and long-acting b 2 -agonist therapy. The most common add-on to inhaled corticosteroid and long-acting b 2 -agonist was leukotriene receptor antagonist (LTRA), followed by long-acting muscarinic receptor antagonist (LAMA) and theophylline (Fig 6A) . The same pattern was noted in the US and UK registries. However, in South Korea, theophylline was used more commonly than was LAMA; in Italy, LAMA was used more commonly than was LTRA. The United Kingdom had the highest proportion of patients receiving add-on LAMA. Add-on therapy was used sparingly in the United States for patients with uncontrolled asthma at GINA Step 4 (at baseline) (Fig 6A) .
Add-on regular OCS was used by almost one-half of the patients at GINA Step 5, anti-IgE and anti-IL-5 were each used by approximately one-third of patients, Anti-IgE and macrolides were prescribed for a minority. A wide range of intercountry variability was noted for regular OCS use (Fig 6B) . Overall, 72.6% of patients with severe asthma at GINA Step 5 were receiving therapeutic monoclonal antibody therapy (ie, biologics), with notably high rates in Italy and the United Kingdom and a relatively low rate of use in South Korea (Fig 6B, Table 4 ). In Italy, the predominant biologic was anti-IgE, but in the United Kingdom it was anti-IL-5. The United States differed from other countries in having a fairly even split between anti-IgE and anti-IL-5 and also the highest proportion of patients receiving macrolides (Fig 6B) .
Discussion
The international population with severe asthma is predominantly female, overweight or obese, nonsmoking, and in the 55-to 79-year age range. There is substantial interregistry heterogeneity in the clinical characteristics of patients treated within severe asthma services. More work is required to explain many of these intercountry differences definitively. We hypothesize that some of these differences may be indicative of variations in cultural and epidemiological patterns, as well as environmental pressures. Other differences could reflect country-specific system issues (eg, differences in patient journey to severe asthma centers, selection bias, treatment landscape). Some differences may be explained by intrinsic differences in the asthma phenotype. ISAR has prioritized numerous research projects to help answer these outstanding questions such as investigating the effect of race, ethnicity, and socioeconomic status on asthma outcomes, assessing variability in biologic access and use (both within and between countries), and comparing OCS use patterns around the world (http://isaregistries. org/isar-research-updates/). South Korea had the oldest patients, likely the result of its aging population, 35 and it has yet to experience the asthma epidemic seen in many Western countries in the past decades. 36 It has also the lowest prevalence of patients who were overweight or obese, perhaps because of the beneficial effect of South Korean traditional diets. 37 The high prevalence of current smokers in South
Korea is in keeping with this older population, who often have ACO, 38 and is supported further by the generally poorer lung function and less reversibility noted for these patients. The relatively late onset of asthma in South Korea may be linked to recent economic development there, and the subsequent spike in air pollution, associated with an increase in hospital admissions for asthma. 39 Conversely, the relatively early age of onset of asthma in the United Kingdom and the SAWD registry may be a consequence of the epidemic of childhood asthma first described in the second one-half of the 20th century. 40 Age of onset could have implications for response to biologic therapy; patients with adult onset tend to respond better to anti-IL-5 or anti-IL-5 receptor, and those with younger onset tend to respond better to antiIgE.
2,41
Other intercountry differences noted could be the result of broad system differences. High numbers of patients at GINA Step 5 in the United Kingdom and Italy may occur because patients come from tertiary asthma centers (with strict referral criteria), so they naturally have the most severe disease. The high numbers with well-controlled asthma in Italy and the low numbers in the United Kingdom and the SAWD registry most likely are because in Italy patients are generally follow-up patients receiving biologic therapy, whereas those from the United Kingdom and the SAWD registry are generally patients at their first visit, before biologic use. These factors also help to explain the high exacerbation rate and HCRU in the United Kingdom, coupled with the fact that at least four exacerbations per year is required for biologic prescription in the United Kingdom. 42, 43 In contrast, the high proportion of patients with well-controlled asthma in South Korea most likely reflects the rapid access to specialist care, which, along with the low cost of medications, may explain the low HCRU there.
The low exacerbation rate noted in the United States is most likely artificial because exacerbation data were not captured directly but rather by proxy and conservatively via OCS use. This is because exacerbations are rarely chestjournal.org coded in the US registry but rather added in the free-text box. Future work to capture this free-text information, as well as comorbidity information, is ongoing and will be provided in future analyses. In the interim, these data provide a useful benchmark to assess whether proxy OCS is a good or bad indicator of exacerbation rate. Definition overlap may account for the high prevalence of CRS (vs AR) in the United States, whereas routine nasal examination of patients in Italy may explain the high prevalence of NPs noted there. The high prevalence of eczema in the SAWD registry may be accounted for by a selection bias toward atopy, a requirement for omalizumab therapy.
Intercountry differences in treatment strategies also were noted. The high OCS and biologic use in both the United Kingdom and Italy may be severity driven. Biologic treatment patterns also differed among these countries, with Italy having high use of anti-IgE, the United Kingdom having high use of anti-IL-5, and the United States exhibiting an even split between anti-IgE and anti-IL-5. These different patterns probably reflect biologic availability or perhaps point to phenotypic differences. The high prevalence of LAMA and LTRA add-on therapy noted in the United Kingdom aligns with British Thoracic Society guideline-directed care for GINA Step 4 44 and is in keeping with treatment at primary care. In South Korea, high regular OCS use (for GINA Step 5) and add-on theophylline and LTRA use (for GINA Step 4) also were noted, but here the drivers may be different (eg, patient preference for oral therapies, 45 availability and reimbursement for these medications). Biologics are not reimbursed in South Korea and rarely used.
This first ISAR data set also facilitates categorization and comparison of asthma biomarker phenotypes across countries. The United Kingdom and Italy appear to have a predominance of helper T cell (Th2)-high, eosinophilic asthma, evidenced by high FENO and BEC. 2, 46, 47 The earlier onset of asthma in the United Kingdom, could indicate a predominance of allergic asthma, whereas the later asthma onset, and high prevalence of NPs in Italy suggest the predominance of a nonallergic phenotype. 48 Although baseline IgE levels may not predict the likelihood of response to biologics, 49 the higher BEC noted in both the United Kingdom and Italy predict a better response, both to anti-IgE 50, 51 and to anti-IL-5
and anti-IL-5 receptor. 52 High exacerbation rates per year noted in both countries and the presence of NPs in
Italy are also factors that may predict a good response to anti-IL-5 therapy. 2 In contrast, the lower BEC and low FENO biomarker profile noted for the SAWD registry is more indicative of a population predominantly with noneosinophilic, Th2-low asthma, whereas the profiles observed in the United States and South Korea registries are more ambiguous and could suggest a split of Th2-high and Th2-low asthma phenotypes (e- Table 6 ).
Merging data from preexisting registries brought its own challenges, including intercountry variability in the type of patients included in registries and standardization of variable definitions, as well as use of retrospective data.
Although there was a bias toward white patients in this first ISAR data set, a much broader ethnic diversity will be contained in future data sets as ISAR continues to expand into Asia, Africa, and South America. A strength of this study is its size and the fact that data collected in registries are more heterogeneous than those collected in randomized controlled trials and are more representative of patients in real life. 53 Use of patientlevel data also provides the opportunity to conduct biostatistical multivariate analyses, track patient progress longitudinally, and analyze response to treatment and changes in medical management. It is important to have both baseline and prospective data to describe the patient journey, to compare a baseline to a postbiologic timeline, and even to answer the question of who develops severe asthma.
Conclusions
This study provides the first description, to our knowledge, of an international population with managed severe asthma, and identified differences in demographic and clinical characteristics across country and health-care systems. Initial countryspecific biomarker profiles have been identified. Whether inter-counter differences are related to underlying epidemiological factors, environmental factors, phenotypes, asthma management systems, treatment access, and/or cultural factors requires further study. Prospective data collection for the ISAR registry began in 2018 in Italy, the United States, South Korea, and the United Kingdom. Prospective data collection will ensure better standardization of data fields, facilitating more accurate cross-country comparisons and reducing any data incongruence in upcoming ISAR data sets.
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